PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF

(19)

(11)

EP 3 344 275 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	12.04.2023 Bulletin 2023/15

(45)	Mention of the grant of the patent:
	08.03.2023 Bulletin 2023/10

(21)	Application number: 16843105.4

(22)	Date of filing: 02.09.2016

(51)

International Patent Classification (IPC):

A61K 31/337^(2006.01)
A61K 31/7068^(2006.01)
A61K 38/15^(2006.01)
A61K 38/50^(2006.01)
A61P 35/00^(2006.01)
A61K 31/437^(2006.01)
A61K 31/475^(2006.01)
A61K 31/519^(2006.01)
A61K 31/565^(2006.01)
A61K 31/664^(2006.01)
A61K 31/555^(2006.01)

A61K 31/357^(2006.01)
A61K 38/12^(2006.01)
A61K 38/21^(2006.01)
A61K 45/06^(2006.01)
A61K 31/436^(2006.01)
A61K 31/44^(2006.01)
A61K 31/506^(2006.01)
A61K 31/553^(2006.01)
A61K 31/573^(2006.01)
A61K 31/706^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 38/12; A61K 38/21; A61K 38/50; A61K 45/06; A61K 31/44; C12Y 305/01001; A61K 31/337; A61K 31/357; A61K 31/555; A61K 33/243; A61K 31/436; A61K 31/437; A61K 31/475; A61K 31/506; A61K 31/519; A61K 31/553; A61K 31/565; A61K 31/573; A61K 31/664; A61K 31/706; A61K 31/7068; A61K 38/15; A61P 35/00; A61P 35/02; A61P 43/00; A61K 38/08

	C-Sets:
	A61K 31/357, A61K 2300/00; A61K 31/337, A61K 2300/00; A61K 31/7068, A61K 2300/00; A61K 31/555, A61K 2300/00; A61K 33/243, A61K 2300/00; A61K 38/21, A61K 2300/00; A61K 38/50, A61K 2300/00; A61K 31/44, A61K 2300/00; A61K 38/15, A61K 2300/00; A61K 38/12, A61K 2300/00;

(86)	International application number:
	PCT/US2016/050194

(87)	International publication number:
	WO 2017/040990 (09.03.2017 Gazette 2017/10)

(54)	PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF PEPTIDOMIMETISCHE MAKROZYKLEN UND VERWENDUNGEN DAVON MACROCYCLES PEPTIDOMIMÉTIQUES ET LEURS UTILISATIONS

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

03.09.2015 US 201562214142 P
18.03.2016 US 201662310254 P
02.06.2016 US 201662344651 P
02.06.2016 US 201662344791 P

(43)	Date of publication of application:
	11.07.2018 Bulletin 2018/28

(73)	Proprietor: Aileron Therapeutics, Inc.
	Boston, MA 02210 (US)

(72)	Inventors:
	AIVADO, Manuel Chester Springs, Pennsylvania 19425 (US) GUERLAVAIS, Vincent Arlington, Massachusetts 02476 (US) OLSON, Karen Waltham, Massachusetts 02451 (US)

(74)	Representative: Avidity IP
	Broers Building Hauser Forum 21 JJ Thomson Avenue Cambridge CB3 0FA Cambridge CB3 0FA (GB)

(56)

References cited: :

WO-A1-2012/021874
WO-A1-2013/123266
WO-A1-2016/049359
WO-A2-2012/021876

WO-A1-2012/021875
WO-A1-2016/049355
WO-A1-2016/154058

CHANG, Y. S. ET AL.: 'Stapled a-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 110, no. 36, 2013, pages E3445 - E3454, XP055333079
BROWN, C. J. ET AL.: 'Stapled peptides with improved potency and specificity that activate p53' ACS CHEMICAL BIOLOGY. vol. 8, no. 3, 2012, pages 506 - 512, XP055139125
AL-LAZIKANI, B. ET AL.: 'Combinatorial drug therapy for cancer in the post- genomic era' NATURE BIOTECHNOLOGY vol. 30, no. 7, 2012, pages 679 - 692, XP055370881
LI, F. ET AL.: 'Molecular-targeted agents combination therapy for cancer: Developments and potentials' INTERNATIONAL JOURNAL OF CANCER. vol. 134, no. 6, 01 January 2014, pages 1257 - 1269, XP055517584 DOI: 10.1002/IJC.28261

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).